# TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY

> **NIH NIH R01** · ROSWELL PARK CANCER INSTITUTE · 1989 · $141,724

## Abstract

Monoclonal antibody F36/22 (IgG3, recognizes a glycoprotein with
Mr of 700-1000K) has been shown immunohistochemically to be
reactive with all human common epithelial ovarian cancers, while
normal ovary expresses no detectable level of immunostain.  Human
exfoliated ovarian tumor cells are usually disseminating throughout
the entire peritoneal cavity, and represent an ideal target for
therapeutic manipulation in a confined compartment.  A recently
available human ovarian carcinoma xenograft in female athymic mice,
NIH:OVCAR_3, expresses antigen recognized by monoclonal antibody
F36/22 and resembles the human disease by producing ascites and
intra-abdominal carcinomatosis.  Using monoclonal antibody F36/22
as the probe and NIH:OVCAR-3 as the in vivo model, we will develop
and eva;iate effective radioimmunotherapy for the targeting and
elimination of peritoneal ovarian tumor seedings.  Adriamycin,
acommonly used cytotoxic agent in ovarian cancer, will be
conjugated to monoclonal antibody F36/22 as the probe and NIH:OVCAR
as the in vivo model, we will develop and evaluate effective
radioimmunotherapy for the targeting and elimination of peritoneal
ovarian tumor seedings.  Adriamycin, a commonly used cytotoxic
agent in ovarian cancer, will be conjugated to monoclonal antibody
F36/22 for intracavity immunochemotherapy of ovarian tumor.
Effectiveness of both therapies will be potentiated by biological
response modifiers.  The proposed approaches to the use of a unique
monoclonal antibody in targeting and therapy of ovarian cancer in
a confined cavity compartment with little or no communication with
toher body compartments will generate defined and useful
preclinical information.

## Key facts

- **NIH application ID:** 3175436
- **Project number:** 5R01CA037646-05
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE
- **Principal Investigator:** Tsann Ming Chu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $141,724
- **Award type:** 5
- **Project period:** 1984-08-15 → 1991-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3175436

## Citation

> US National Institutes of Health, RePORTER application 3175436, TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY (5R01CA037646-05). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3175436. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*